AANEM News Express

AANEM News Express

Myasthenia Gravis Treated with Autologous Hematopoietic Stem Cell Transplantation

12/14/2016
 
Bryant A, Atkins H, Pringle CE, et al. Myasthenia Gravis Treated with Autologous Hematopoietic Stem Cell Transplantation. JAMA Neurol 2016;73:652-658.

Submitted by Niranjan N. Singh, MD, News Science Editorial Board
The authors report a series of seven patients (two of whom were seronegative) with severe myasthenia gravis treated with autologous hematopoietic stem cell transplantation. Patients were refractory to treatment with multiple treatment modalities including pyridostigmine, corticosteroids, azathioprine, mycophenolate mofetil, cyclosporine, intravenous immunoglobulin, plasma exchange, and thymectomy. The protocol included graft mobilization and purification, treatment with intensive conditioning chemotherapy, and graft reinfusion. All patients achieved complete stable remission with no residual myasthenia gravis symptoms or requirement for disease-modifying therapy.


Comment: Refractory myasthenia gravis accounts for 10% of disease. Hematopoietic stem cell transplantation offers a potential treatment option for patients in this group. It should be emphasized that this study is a retrospective case series, and that stem cell transplantation has not been studied in a prospective fashion in patients with myasthenia gravis.


About the AANEM News Science Editorial Board

The board helps to highlight significant, timely science news items for AANEM members. It reviews articles in journals and websites, identifies newsworthy items in the field, and writes article summaries.


View Related News Stories:

  Practice


Recent AANEM News

Science News: A Novel Treatment Strategy for Severe Guillain-Barre Syndrome: The Zipper Method

Science News: Six-Month Assessment of a Hand Prosthesis with Intraneural Tactile Feedback

Dr. Peter Grant’s Expert Testimony Helps Convict Texas Doctor and Hospital Owner in $20 Million Healthcare Fraud Scheme

Science News: High Prevalence of Neutralizing Antibodies After Long-term Botulinum Neurotoxin Therapy

Submit Your Abstract for the Myasthenia Gravis Foundation of America’s 2019 Scientific Session!





Advertisement

TPP

Advertisement

ABEM

Advertisement

Find Your Dream Job